NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 22 pharmaceutical companies such as NOVAST LABS, INGENUS PHARMS NJ, DR REDDYS LABS SA and others. It is marketed under 11 brand names, including CARISOPRODOL AND ASPIRIN, CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, OXYCODONE AND ASPIRIN and others. Available in 14 different strengths, such as 325MG;200MG, 325MG;200MG;16MG, 325MG;4.8355MG and others, and administered through 4 routes including TABLET;ORAL, CAPSULE;ORAL, CAPSULE, EXTENDED RELEASE;ORAL and others.
API availability: Loading API feasibility...
Licensing: 22 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"52417","ingredient":"ASPIRIN","trade_name":"VAZALORE","family_id":"7266c921815647bf86f5","publication_number":"US10646431B2","cleaned_patent_number":"10646431","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-09-29","publication_date":"2020-05-12","legal_status":"Granted"} | US10646431B2 Formulation | 12 May, 2020 | Granted | 29 Sep, 2032 | |
| {"application_id":"52418","ingredient":"ASPIRIN","trade_name":"VAZALORE","family_id":"7266c921815647bf86f5","publication_number":"US10786444B2","cleaned_patent_number":"10786444","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-09-29","publication_date":"2020-09-29","legal_status":"Granted"} | US10786444B2 | 29 Sep, 2020 | Granted | 29 Sep, 2032 | |
| {"application_id":"52414","ingredient":"ASPIRIN","trade_name":"VAZALORE","family_id":"7266c921815647bf86f5","publication_number":"US9216150B2","cleaned_patent_number":"9216150","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-09-29","publication_date":"2015-12-22","legal_status":"Granted"} | US9216150B2 Formulation | 22 Dec, 2015 | Granted | 29 Sep, 2032 | |
| {"application_id":"52400","ingredient":"ASPIRIN","trade_name":"VAZALORE","family_id":"7266c921815647bf86f5","publication_number":"US9226892B2","cleaned_patent_number":"9226892","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-09-29","publication_date":"2016-01-05","legal_status":"Granted"} | US9226892B2 | 05 Jan, 2016 | Granted | 29 Sep, 2032 | |
| {"application_id":"84412","ingredient":"ASPIRIN; OMEPRAZOLE","trade_name":"YOSPRALA","family_id":"438a1a6e6b2f48b9b02d","publication_number":"US9987231B2","cleaned_patent_number":"9987231","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-01-02","publication_date":"2018-06-05","legal_status":"Expired"} | US9987231B2 | 05 Jun, 2018 | Expired | 02 Jan, 2033 | |
| {"application_id":"84404","ingredient":"ASPIRIN; OMEPRAZOLE","trade_name":"YOSPRALA","family_id":"438a1a6e6b2f48b9b02d","publication_number":"US9539214B2","cleaned_patent_number":"9539214","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-13","publication_date":"2017-01-10","legal_status":"Granted"} | US9539214B2 | 10 Jan, 2017 | Granted | 13 Mar, 2033 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Aspirin
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.